GlassScriptPhysician profile
Timothy R Williams
NPI 1790731446
$1,666.23
in general payments reported to CMS, 2019-2025
26 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $36.45 · 2021: $94.23 · 2022: $361 · 2023: $260 · 2024: $230 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $376.56 | 2022-2025 | Tagrisso, Lynparza |
| Varian Medical Systems, INC. | $328.48 | 2019 | |
| Seagen INC. | $172.33 | 2022-2023 | Tivdak |
| Tesaro, INC. | $124.08 | 2019 | |
| Emd Serono, INC. | $63.80 | 2022 | |
| Blue Earth Diagnostics | $61.60 | 2020-2025 | Posluma |
| Palette Life Sciences, INC. | $50.03 | 2023 | |
| Eisai INC. | $48.52 | 2021-2022 | |
| Janssen Biotech, INC. | $45.86 | 2024 | Erleada, Rybrevant |
| Boston Scientific Corporation | $42.42 | 2021-2023 | Spaceoar Vue System - 10ml |
| Bioprotect Medical, INC. | $39.22 | 2024-2025 | Bioprotect Balloon Implant System |
| Merck Sharp & Dohme LLC | $37.67 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35.33 | 2022 | |
| Lilly USA, LLC | $33.76 | 2023 | Retevmo |
| Davol INC. | $27.31 | 2025 | Arista |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hitachi Healthcare Americas Corp. | $26.04 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.63 | 2022 | |
| Astellas Pharma US INC | $21.55 | 2019 | |
| Myriad Genetic Laboratories, INC. | $20.19 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.12 | 2023 | Zepzelca |
| Alexion Pharmaceuticals, INC. | $16.75 | 2024 | Ultomiris |
| Morphosys, US INC. | $15.90 | 2021 | |
| Tactile Systems Technology INC | $14.06 | 2021 | |
| Angiodynamics, INC. | $11.71 | 2019 | |
| Fortovia Therapeutics, INC. | $10.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.